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angiographic parameters cannot and should not be used as a
surrogate for coronary flow.
Finally, recent data by Sant’Anna et al. (12) challenge our
assumptions regarding whether angiographic 3-vessel disease is
truly physiological 3-vessel disease. Of the 250 patients undergo-
ing angiography, when the 27% of patients with angiographic
3-vessel disease had FFR measured in all 3 of these vessels, only
9% were found to have physiologically significant 3-vessel coronary
disease. Had bypass grafting been performed, a considerable
incidence of graft failure would be expected at follow-up. Fortu-
nately, in this setting graft failure is often clinically silent with the
consequences of graft closure across nonsignificant lesions revert-
ing to the native vessel, which remains patent and functional
(unless the lesion progresses).
Whereas the debate about the use of the GEA graft continues,
a critical question before the surgery for those vessels with
intermediately severe stenoses should be answered by direct phys-
iologic measurements: is a graft on this particular vessel going to be
of any use if the physiology is nearly normal (13)?
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Reply
Dr. Kern wisely raised several points that were not discussed in our
article (1). We are convinced of the interest of fractional flow
reserve (FFR) as a tool to asses the physiological relevance of
coronary stenoses, and we recently used this tool to compare the
resistance to blood flow of several coronary graft configurations
(2,3). Unfortunately, if all patients referred to bypass surgery
underwent a pre-operative angiographic evaluation and if most of
those angiographic documents could be analyzed quantitatively,
very few patients would be referred to surgery with a full mapping
of FFR on the different coronary segments.
In daily clinical practice, the use of FFR remains generally
restricted to the evaluation of stenoses of intermediate severity and
mainly in patients with 3-vessel disease who are planned to be
treated by interventional cardiology. For patients referred to
surgery with a 2- or 3-vessel disease, the decision to measure FFR
for an intermediate stenosis associated with angiographically severe
narrowing on other coronary segments is much less frequent,
because the surgical indication is already present, on the basis of
the critical lesions. In these cases, most cardiac surgeons choose to
graft the intermediate lesion as well, even if this bypass is at risk of
competitive flow. This attitude, although somewhat empirical, is
based on the low risk expected from the possible occlusion of such
nonfunctional grafts, on the hope that these grafts will remain
patent long enough to provide some help in the case of progression
of the intermediate lesion, and on the fear of a redo intervention,
if lesion severity is underestimated. It still remains uncertain
whether this is preferable to a more conservative attitude consisting
of graft implantation only on severely narrowed coronary segments.
Several observations have illustrated the capacity of the internal
thoracic artery (4) or right gastroepiploic artery (RGEA) (5) to
recover function in the long term after having been found not
functional (string sign) at early follow-up. This capacity seems
related to endothelial protection mechanisms that are probably less
prominent or totally absent in saphenous vein graft. Considering
the natural progression of the disease on native vessels, this
property could act in favor of RGEA in the longer term. The
ongoing angiographic re-evaluation of the grafts at 3 years post-
operatively could thus provide information susceptible to clarifying
the meaning of these early findings, particularly in RGEA grafts
with a balanced flow.
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